Navigation Links
Using coxibs and NSAIDs to treat osteoarthritis
Date:8/13/2007

Mt Laurel, NJ 13 August 2007 - In an Editorial, to be published in the international journal Osteoarthritis and Cartilage (http://intl.elsevierhealth.com/journals/joca/), published by Elsevier, a panel of arthritis research experts has recommended that coxibs and nonsteroidal anti-inflammatory drugs (NSAIDs) must remain a significant part of the tool kit used in treating osteoarthritis (OA). The Editorial summarizes the outcomes of an international workshop organized by the Osteoarthritis Research Society International (OARSI) and the International COX-2 Study Group, held 2425 March 2007. The authors urge that an evidence-based approach must be taken when making recommendations to patients.

OA, the most common form of arthritis, is a major medical problem. It has been estimated that over 20 million Americans are afflicted with OA, and that number will rise to 40 million by the year 2020. Controversy now exists as to the safest and most efficacious way of treating the disease, particularly with respect to use of NSAIDs, both non-selective and selective (so-called COX-2 selective agents or coxibs). Adverse reactions related to the gastrointestinal tract, particularly with the non-selective NSAIDs, have been described; more recently, concerns have been expressed related to the cardiovascular system with both groups of agents.

A recent scientific statement from the American Heart Association (AHA) made recommendations with regard to the treatment of OA.1 A number of these recommendations are challenged in the Editorial2 in Osteoarthritis and Cartilage, with particular concern about their impact on appropriate use of these agents.

The Editorial questions the recommendation made in the AHA statement which described a stepped care approach to pharmacologic therapy for musculoskeletal diseases. The Editorial strongly recommends that several aspects of the AHA statement be reconsidered. For example, it urges that the AHA withdraw their non-evidence-based recommendations that high-dose aspirin be administered alone as a first line therapy for patients with chronic pain and arthritis.

Dr Roland W. Moskowitz, Professor of Medicine at Case Western Reserve University/University Hospitals of Cleveland, lead author of the Editorial comments, "Careful review of the pros and cons of using these agents, and the situations in which they are most safely and effectively used, is required to help us understand how best to take advantage of their availability".

The input by the OARSI/COX-2 International Study Group provides evidence-based background and guidance that will be of help to physicians, and to patients, in the use of these important commonly used agents.


'/>"/>
Contact: Ian Salusbury
ian.salusbury@elsevier.com
44-186-584-3000
Elsevier
Source:Eurekalert

Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
3. Researchers urge caution in using ear tube surgery
4. Ulcer causing bug found in stored food
5. Using Stem Cells To Treat Incontinence In Women
6. Flu-Drugs Are Causing Resistance Across The World
7. Researchers at Cornell University as been reported using research fund by false claims
8. Relief to pregnant women using fertility drugs
9. The hazards of using disinfectant hand gel
10. Colon cancer risk linked to genes causing Hemochromatosis
11. Teens Misusing Nicotine-Replacement Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... "FCPX LUT Intense allows users to cycle through ... Austin - CEO of Pixel Film Studios. , With the FCPX LUT Intense ... color grades to their footage. A LUT is a Lookup Table that contains a ...
(Date:5/25/2016)... GA (PRWEB) , ... May 25, 2016 , ... ... solutions builder, has announced that it will join America's leading engineers at the ... be held at the Georgia World Congress Center. , Engineers, speakers and ...
(Date:5/24/2016)... ... 24, 2016 , ... BTC Media, a leading digital currency ... to be held in Nashville, Tennessee on September 7, 2016. , The conference ... the event will host teams from around the world, competing to build the ...
(Date:5/24/2016)... ... May 24, 2016 , ... i2i, a national ... website at its “Transforming Outcomes” User Conference in Las Vegas on May 19-20, ... success to set the market standard for meaningful population health management. The ...
(Date:5/24/2016)... ... May 24, 2016 , ... Local engineering firm, Timmons Group, ... Center located in Woodbridge, VA. The project includes a brand new operating ... , The new 2 story building houses the Central Sterile department, Sterile prep ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
(Date:5/24/2016)... HENDERSON, Nev. , May 24, 2016  Diana ... painfully "eats" her organs from the inside out.  This ... her completely dependent on her children and grandchildren to ... of her wheelchair, Diana,s family cannot haul the wheelchair.  ... rides in the car, and Diana is left to ...
(Date:5/24/2016)... , May 24, 2016 ... the world , s first dual ... fistula intervention   OrbusNeich, a global company ... expanded its portfolio to include products to treat peripheral ... the company,s first entry devices for lower limb and ...
Breaking Medicine Technology: